NCT03016338 2024-01-30
Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer
University Health Network, Toronto
Phase 2 Unknown
Clinical Trials
12 trialsNCT05065021 2024-01-17
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
University Health Network, Toronto
Phase 2 Unknown
NCT03088059 2023-11-03
UPSTREAM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Unknown
NCT03654833 2023-03-14
MiST
University of Leicester
Phase 2 Unknown
NCT05641506 2022-12-07
A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT05162196 2022-05-02
The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer
Wuhan University
Phase 2 Unknown
NCT05311579 2022-04-13
Niraparib Plus Anlotinib for Recurrent Ovarian Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT03925350 2021-10-22
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation
California Pacific Medical Center Research Institute
Phase 2 Unknown
NCT04217798 2021-09-01
Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04885413 2021-08-23
An Open-label, Single Arm, Phase II Trial of Niraparib in Combination With Anti-PD1（Programmed Cell Death Protein 1） Antibody in Recurrent/ Advanced Stage Endometrial Cancer Patients
Sun Yat-sen University
Phase 2 Unknown
NCT04715620 2021-01-20
Niraparib Combined With Radiotherapy in rGBM
Tianjin Huanhu Hospital
Phase 2 Unknown
NCT04376073 2020-11-25
ANNIE
Sun Yat-sen University
Phase 2 Unknown